Cart
Account
Your Orders
Sign In
We’re excited to make two major announcements today. We have closed a $110M Series C investment round led by Founders Fund and we have added Dr. Matthew Porteus, a pioneer in cell therapies, to our advisory board.
Since the start of our journey at Synthego, we’ve been committed to making state-of-the-art genome engineering tools accessible to researchers and scientists around the world. We’ve built software products to aid the design and analysis of CRISPR edits, developed synthetic sgRNA editing kits with guaranteed performance, built some of the world’s best models of CRISPR dynamics, and brought online a platform enabling on-demand gene knockouts in over 700 different cell lines.
It’s been humbling to witness the rapid adoption of our products amongst scientists across a wide range of applications. Their creativity and achievements continue to motivate us to build the next generation of genome editing products and technologies.
Towards Accessible Cell and Gene Therapies
Informing this next generation of genome editing technologies requires next-generation thinking. This is why we are excited to welcome Dr. Matthew Porteus to our advisory board. Dr. Porteus’s background as co-founder of CRISPR Therapeutics, a practicing clinician, a Synthego customer, and a leading researcher in cell & gene therapies brings a detailed understanding of what is required to accelerate the development of genome editing and make cell & gene therapies more accessible. Dr. Porteus joins Dr. Jennifer Doudna, co-inventor of CRISPR, on Synthego’s advisory board.
Fueling the Mission
Along with Dr. Porteus joining our advisory board, we’re pleased to announce the closing of a $110 million Series C investment, led by Founders Fund with participation from 8VC, Menlo Ventures, and others. This new capital will allow us to grow our manufacturing reach and abilities in the CRISPRevolution and Engineered Cells offerings, develop new products and platforms, and accelerate our hiring across the organization. This round of financing wouldn’t have been possible without our customers, the employees of Synthego, and the support of our investors; all of whom are key to Synthego’s continued success.
Join the Mission
The opportunity to shape the future in a significant way should not be taken lightly. We welcome the challenges we will face as we build the genome engineering platform for scientists around the world.
Tackling these challenges requires a diverse set of individuals from a wide variety of disciplines across engineering, science, operations, and business. We’re aggressively seeking driven, philosophically-aligned individuals for many roles to support our mission – a mission that has the potential to address material scarcity, rid the world of genetic diseases, and further mankind’s relationship with nature.
Thank You
Thank you for believing in our mission, and supporting us along our journey. We’re excited to step into the next chapter with you. Don’t hesitate to reach out with any thoughts, ideas or questions!
